Фиксированные комбинации в фармакотерапии хронических заболеваний вен

Хронические заболевания вен представляют собой самую распространенную сосудистую патологию нижних конечностей, оказывающую негативное влияние на все составляющие качества жизни современного человека. В силу высокой распространенности профилактика и лечение хронических заболеваний вен являются одной из приоритетных задач национальных систем здравоохранения индустриально развитых стран. Многочисленные экспериментальные и клинические исследования, проведенные в последние годы, выявили важную роль в патогенезе хронических заболеваний вен сосудистого воспаления и дисфункции эндотелия, определяющих не только широкий спектр веноспецифических симптомов, но и запускающих процесс патологического ремоделирования стенки вены и ее клапанного аппарата, с последующим развитием варикозного синдрома и более тяжелых форм хронической венозной недостаточности. Современные представления о патогенезе хронических заболеваний вен позволяют выделить несколько приоритетных стратегий, направленных на коррекцию основных патофизиологических механизмов развития и прогрессирования заболевания. Одной из них выступает фармакотерапия с применением флеботропных препаратов, некоторые из которых способны подавлять веноспецифическое воспаление, улучшать состояние микроциркуляторного русла, повышать тонус и сократимость вен и, как следствие, положительно влиять на клинические проявления хронического заболевания вен. В данном обзоре представлен механизм действия нового для Российской Федерации флеботропного препарата, представляющего собой комбинацию экстракта корневищ иглицы колючей, гесперидина метилхалкона и аскорбиновой кислоты. Препарат обладает высоким уровнем доказательств клинической эффективности и безопасности для пациентов с различными формами хронических заболеваний вен. Исходя из уникальной особенности его механизмов действия оптимальными фокус-группами для его применения могут стать пациенты различных возрастных групп с начальными стадиями заболевания, в которых доминируют веноспецифические симптомы, и больные с хроническим венозным отеком.

1. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005;15(3):175–184. https://doi.org/10.1016/j.annepidem.2004.05.015.

2. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F; VCP Coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://www.minervamedica.it/en/journals/international-angiology/article.php?cod=R34Y2012N02A0105&acquista=1.

3. Wrona M, Jockel KH, Pannier F, Bock E, Hoffmann B, Rabe E. Association of Venous Disorders with Leg Symptoms: Results from the Bonn Vein Study 1. Eur J Vasc Endovasc Surg. 2015;50(3):360–367. https://doi.org/10.1016/j.ejvs.2015.05.013

4. Lee AJ, Robertson LA, Boghossian SM, Allan PL, Ruckley CV, Fowkes FG, Evans CJ. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord. 2015;3(1):18–26. https://doi.org/10.1016/j.jvsv.2014.09.008.

5. Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global Epidemiology of Chronic Venous Disease: A Systematic Review With Pooled Prevalence Analysis. Ann Surg. 2021;274(6):971–976. https://doi.org/10.1097/SLA.0000000000004631.

6. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4(4):CD003229. https://doi.org/10.1002/14651858.CD003229.

7. Mazzaccaro D, Muzzarelli L, Modafferi A, Righini PC, Settembrini AM, Nano G. Use of venoactive drugs after surgery for varicose veins: a preliminary study. Int Angiol. 2018;37(1):79–84. https://doi.org/10.23736/S0392-9590.17.03875-5.

8. Mansilha A, Sousa J. Benefits of venoactive drug therapy in surgical or endovenous treatment for varicose veins: a systematic review. Int Angiol. 2019;38(4):291–298. https://doi.org/10.23736/S0392-9590.19.04216-0.

9. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S0392-9590.18.03999-8.

10. De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024.

11. Gloviczki P, Lawrence PF, Wasan SM, Meissner MH, Almeida J, Brown KR et al. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine. J Vasc Surg Venous Lymphat Disord. 2024;12(1):101670. https://doi.org/10.1016/j.jvsv.2023.08.011.

12. Masullo M, Pizza C, Piacente S. Ruscus Genus: A Rich Source of Bioactive Steroidal Saponins. Planta Med. 2016;82(18):1513–1524. https://doi.org/10.1055/s-0042-119728.

13. Rodrigues JPB, Fernandes Â, Dias MI, Pereira C, Pires TCSP, Calhelha RC et al. Phenolic Compounds and Bioactive Properties of Ruscus aculeatus L. (Asparagaceae): The Pharmacological Potential of an Underexploited Subshrub. Molecules. 2021;26(7):1882. https://doi.org/10.3390/molecules26071882.

14. Niu SL, Hao JH, Xu JY, Guan Q, Zhou ZC, Lv TM, Sun YT. Aculebiphenyl A–B, new biphenyl derivatives from Ruscus aculeatus. J Asian Nat Prod Res. 2023;25(11):1076–1084. https://doi.org/10.1080/10286020.2023.2254702.

15. Redman DA. Ruscus aculeatus (butcher’s broom) as a potential treatment for orthostatic hypotension, with a case report. J Altern Complement Med. 2000;6(6):539–549. https://doi.org/10.1089/acm.2000.6.539.

16. Dunouau C, Bellé R, Oulad-Ali A, Anton R, David B. Triterpenes and sterols from Ruscus aculeatus. Planta Med. 1996;62(2):189–190. https://doi.org/10.1055/s-2006-957858.

17. de Combarieu E, Falzoni M, Fuzzati N, Gattesco F, Giori A, Lovati M, Pace R. Identification of Ruscus steroidal saponins by HPLC-MS analysis. Fitoterapia. 2002;73(7–8):583–596. https://doi.org/10.1016/s0367-326x(02)00220-4.

18. Mimaki Y, Kuroda M, Kameyama A, Yokosuka A, Sashida Y. Aculeoside B, a new bisdesmosidic spirostanol saponin from the underground parts of Ruscus aculeatus. J Nat Prod. 1998;61(10):1279–1282. https://doi.org/10.1021/np9704563.

19. De Marino S, Festa C, Zollo F, Iorizzi M. Novel steroidal components from the underground parts of Ruscus aculeatus L. Molecules. 2012;17(12):14002–14014. https://doi.org/10.3390/molecules171214002.

20. Шайдаков ЕВ, Росуховский ДА. Эффективность комбинации экстракта иглицы, гесперидина и витамина С в лечении хронических заболеваний вен. Ангиология и сосудистая хирургия. 2021;27(2):82–91. https://doi.org/10.33529/ANGIO2021208.

21. Jawien A, Bouskela E, Allaert FA, Nicolaïdes AN. The place of Ruscus extract, hesperidin methyl chalcone, and vitamin C in the management of chronic venous disease. Int Angiol. 2017;36(1):31–41. https://doi.org/10.23736/S0392-9590.16.03788-3.

22. Bouskela E, Cyrino FZ, Marcelon G. Effects of Ruscus extract on the internal diameter of arterioles and venules of the hamster cheek pouch microcirculation. J Cardiovasc Pharmacol. 1993;22(2):221–224. https://doi.org/10.1097/00005344-199308000-00008.

23. Bouskela E, Cyrino FZ, Marcelon G. Possible mechanisms for the venular constriction elicited by Ruscus extract on hamster cheek pouch. J Cardiovasc Pharmacol. 1994;24(1):165–170. https://doi.org/10.1097/00005344-199407000-00025.

24. Rauly-Lestienne I, Heusler P, Cussac D, Lantoine-Adam F, de Almeida Cyrino FZG, Bouskela E. Contribution of muscarinic receptors to in vitro and in vivo effects of Ruscus extract. Microvasc Res. 2017;114:1–11. https://doi.org/10.1016/j.mvr.2017.05.005.

25. de Souza MDGC, Cyrino FZGA, Sicuro FL, Bouskela E. Effects of Ruscus extract on muscarinic receptors: Is there a role for endothelium derived relaxing factors on macromolecular permeability protection and microvascular diameter changes? Clin Hemorheol Microcirc. 2021;77(4):443–459. https://doi.org/10.3233/CH-201019.

26. Allaert FA. Combination of Ruscus aculeatus extract, hesperidin methyl chalcone and ascorbic acid: a comprehensive review of their pharmacological and clinical effects and of the pathophysiology of chronic venous disease. Int Angiol. 2016;35(2):111–116. Available at: https://www.researchgate.net/publication/303027751_Combination_of_Ruscus_aculeatus_extract_hesperidin_methyl_chalcone_and_ascorbic_acid_A_comprehensive_review_of_their_pharmacological_and_clinical_effects_and_of_the_pathophysiology_of_chronic_venous_d.

27. Wang Y, Liu B, Ma Y, Wang C, Ma H, Geng S. Oil/water interface behavior of hesperidin methylchalcone and its application in nanoemulsions. Food Chem. 2024;463(Pt 2):141235. https://doi.org/10.1016/j.foodchem.2024.141235.

28. Zhang J, Song N, Liu Y, Guo J. Platycodin D Inhibits β-Amyloid-Induced Inflammation and Oxidative Stress in BV-2 Cells Via Suppressing TLR4/NF-κB Signaling Pathway and Activating Nrf2/HO-1 Signaling Pathway. Neurochem Res. 2021;46(3):638–647. https://doi.org/10.1007/s11064-020-03198-6.

29. Jafni S, Sathya S, Arunkumar M, Kiruthiga C, Jeyakumar M, Murugesh E, Devi KP. Hesperidin Methyl Chalcone reduces extracellular Aβ(25-35) peptide aggregation and fibrillation and also protects Neuro 2a cells from Aβ(25-35) induced neuronal dysfunction. Bioorg Med Chem. 2023;96:117536. https://doi.org/10.1016/j.bmc.2023.117536.

30. Pinho-Ribeiro FA, Hohmann MS, Borghi SM, Zarpelon AC, Guazelli CF, Manchope MF et al. Protective effects of the flavonoid hesperidin methyl chalcone in inflammation and pain in mice: role of TRPV1, oxidative stress, cytokines and NF-κB. Chem Biol Interact. 2015;228:88–99. https://doi.org/10.1016/j.cbi.2015.01.011.

31. Man MQ, Yang B, Elias PM. Benefits of Hesperidin for Cutaneous Functions. Evid Based Complement Alternat Med. 2019;2019:2676307. https://doi.org/10.1155/2019/2676307.

32. Kakkos SK, Bouskela E, Jawien A, Nicolaides AN. New data on chronic venous disease: a new place for Cyclo 3® Fort. Int Angiol. 2018;37(1):85–92. https://doi.org/10.23736/S0392-9590.17.03935-9.

33. Kim HY, Park M, Kim K, Lee YM, Rhyu MR. Hesperetin Stimulates Cholecystokinin Secretion in Enteroendocrine STC-1 Cells. Biomol Ther. 2013;21(2):121–125. https://doi.org/10.4062/biomolther.2012.077.

34. Xiong H, Wang J, Ran Q, Lou G, Peng C, Gan Q et al. Hesperidin: A Therapeutic Agent For Obesity. Drug Des Devel Ther. 2019;13:3855–3866. https://doi.org/10.2147/DDDT.S227499.

35. Morshedzadeh N, Ramezani Ahmadi A, Behrouz V, Mir E. A narrative review on the role of hesperidin on metabolic parameters, liver enzymes, and inflammatory markers in nonalcoholic fatty liver disease. Food Sci Nutr. 2023;11(12):7523–7533. https://doi.org/10.1002/fsn3.3729.

36. Taheri A, Mobaser SE, Golpour P, Nourbakhsh M, Tavakoli-Yaraki M, Yarahmadi S, Nourbakhsh M. Hesperetin attenuates the expression of markers of adipose tissue fibrosis in pre-adipocytes. BMC Complement Med Ther. 2023;23(1):315. https://doi.org/10.1186/s12906-023-04152-z.

37. Lykkesfeldt J, Michels AJ, Frei B. Vitamin C. Adv Nutr. 2014;5(1):16–18. https://doi.org/10.3945/an.113.005157.

38. Hemilä H. Vitamin C supplementation and the common cold--was Linus Pauling right or wrong? Int J Vitam Nutr Res. 1997;67(5):329–335. Available at: https://www.mv.helsinki.fi/home/hemila/H/HH_1997_IJVNR.pdf.

39. Carr AC, Lykkesfeldt J. Vitamin C: From Bench to Bedside. Nutrients. 202127;13(4):1102. https://doi.org/10.3390/nu13041102.

40. Padayatty SJ, Levine M. Vitamin C: the known and the unknown and Goldilocks. Oral Dis. 2016;22(6):463–493. https://doi.org/10.1111/odi.12446.

41. Gref R, Deloménie C, Maksimenko A, Gouadon E, Percoco G, Lati E et al. Vitamin C-squalene bioconjugate promotes epidermal thickening and collagen production in human skin. Sci Rep. 2020;10(1):16883. https://doi.org/10.1038/s41598-020-72704-1.

42. Sansilvestri-Morel P, Rupin A, Badier-Commander C, Fabiani JN, Verbeuren TJ. Chronic venous insufficiency: dysregulation of collagen synthesis. Angiology. 2003;54 (Suppl. 1):S13–S18. https://doi.org/10.1177/0003319703054001S03.

43. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. JAMA. 1999;281(15):1415–1423. https://doi.org/10.1001/jama.281.15.1415.

44. Sauberlich HE. Pharmacology of vitamin C. Annu Rev Nutr. 1994;14:371–391. https://doi.org/10.1146/annurev.nu.14.070194.002103.

45. Tu Z, Yang J, Fan C. The role of different nutrients in the prevention and treatment of cardiovascular diseases. Front Immunol. 2024;15:1393378. https://doi.org/10.3389/fimmu.2024.1393378.

46. Kocot J, Luchowska-Kocot D, Kiełczykowska M, Musik I, Kurzepa J. Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders? Nutrients. 2017;9(7):659. https://doi.org/10.3390/nu9070659.

47. Mayrovitz HN, Aoki KC, Colon J. Chronic Venous Insufficiency With Emphasis on the Geriatric Population. Cureus. 2023;15(6):e40687. https://doi.org/10.7759/cureus.40687.

48. de Almeida Cyrino FZG, Balthazar DS, Sicuro FL, Bouskela E. Effects of venotonic drugs on the microcirculation: Comparison between Ruscus extract and micronized diosmine. Clin Hemorheol Microcirc. 2018;68(4):371–382. https://doi.org/10.3233/CH-170281.

49. Dai Y, Zhou Q, Liu Y, Chen X, Li F, Yu B et al. Ruscogenin Alleviates Deep Venous Thrombosis and Pulmonary Embolism Induced by Inferior Vena Cava Stenosis Inhibiting MEK/ERK/Egr-1/TF Signaling Pathway in Mice. Curr Pharm Des. 2022;28(24):2001–2009. https://doi.org/10.2174/1381612828666220526120515.

50. Monjotin N, Tenca G. Lymphotonic activity of Ruscus extract, hesperidin methyl chalcone and vitamin C in human lymphatic smooth muscle cells. Microvasc Res. 2022;139:104274. https://doi.org/10.1016/j.mvr.2021.104274.

51. Bouskela E, Cyrino FZ, Bougaret S. Effects of Cyclo 3 Fort on microvascular reactivity and the venoarteriolar reflex in diabetic hamsters. Clin Hemorheol Microcirc. 1997;17(5):351–356. Available at: https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/clin044.

52. Kakkos SK, Allaert FA. Efficacy of Ruscus extract, HMC and vitamin C, constituents of Cyclo 3 fort®, on improving individual venous symptoms and edema: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2017;36(2):93–106. https://doi.org/10.23736/S0392-9590.17.03815-9.

53. Allaert FA, Hugue C, Cazaubon M, Renaudin JM, Clavel T, Escourrou P. Correlation between improvement in functional signs and plethysmographic parameters during venoactive treatment (Cyclo 3 Fort). Int Angiol. 2011;30(3):272–277. Available at: https://www.minervamedica.it/en/journals/international-angiology/article.php?cod=R34Y2011N03A0272.

54. Aguilar Peralta GR, Arévalo Gardoqui J, Llamas Macías FJ, Navarro Ceja VH, Mendoza Cisneros SA, Martínez Macías CG. Clinical and capillaroscopic evaluation in the treatment of chronic venous insufficiency with Ruscus aculeatus, hesperidin methylchalcone and ascorbic acid in venous insufficiency treatment of ambulatory patients. Int Angiol. 2007;26(4):378–384. Available at: https://pubmed.ncbi.nlm.nih.gov/18091707/.

55. Urbanek T The clinical efficacy of Ruscus Aesculatus extract: is there enough evidence to update the pharmacotherapy guidelines for chronic venous disease? Phlebol Rev. 2017;25(1):75–80. https://doi.org/10.5114/pr.2017.70594.

56. Хрыщанович ВЯ, Роговой НА, Скобелева НЯ, Красько ОВ. Эффективность компрессионной и флеботропной терапии варикозной болезни у беременных. Амбулаторная хирургия. 2023;20(1):94–104. https://doi.org/10.21518/akh2022-007.

57. Guex JJ, Avril L, Enrici E, Enriquez E, Lis C, Taïeb C. Quality oflife improvement in Latin American patients suffering from chronic venous disorder using a combination of Ruscus aculeatus and hesperidin methyl-chalcone and ascorbic acid (quality study). Int Angiol. 2010;29(6):525–532. Available at: https://www.minervamedica.it/en/journals/international-angiology/article.php?cod=R34Y2010N06A0525.

58. Beltramino R, Penenory A, Buceta AM. An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort® versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Angiology. 2000;51(7):535–544. https://doi.org/10.1177/000331970005100702

59. Monteil Seurin J. Insuffisance veino lymphatique: étude comparative de Cyclo 3 Fort® versus diosmine micronisée. C R Ther Pharmacol Clin. 1993;109:3–7. Available at: https://typeset.io/papers/insuffisance-veino-lymphatique-etude-comparative-cyclo-3-5f42h1qnq4.

60. Bihari I, Guex JJ, Jawien A, Szolnoky G. Clinical Perspectives and Management of Edema in Chronic Venous Disease-What about Ruscus? Medicines. 2022;9(8):41. https://doi.org/10.3390/medicines9080041.

61. Cluzan RV, Alliot F, Ghabboun S, Pascot M. Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT. Lymphology. 1996;29(1):29–35. Available at: https://pubmed.ncbi.nlm.nih.gov/8721977/.

62. Gianesini S, Obi A, Onida S, Baccellieri D, Bissacco D, Borsuk D et al. Global guidelines trends and controversies inlower limb venous andlymphatic disease: Narrative literature revision and experts’ opinions following the vWINter international meeting in Phlebology, Lymphology & Aesthetics, 23-25 January 2019. Phlebology. 2019;34(1 Suppl.):4–66. https://doi.org/10.1177/0268355519870690.